sdf

Turkey Receives Over 1.2 Million Patients for Treatment in 2023, Representing a 15% Increase from 2022

Istanbul, May 21, 2024 - Turkey's medical tourism sector continued its momentum, as 2023 witnessed the reception of more than 1.2 million patients from around the world for treatment in Turkish hospitals and medical centers, representing a 15% increase from 2022.

  • This remarkable increase is attributed to several factors, the most important of which are:

    The well-established reputation of Turkish hospitals and medical centers: Turkish hospitals and medical centers have gained a global reputation for the quality of their medical services, the expertise of their doctors, and the availability of the latest medical technologies at affordable prices.

      Availability of various medical specialties: Turkish hospitals offer a wide range of medical specialties, including cardiac surgery, orthopedics, plastic surgery, organ transplantation, cancer treatment, and others.

        Distinctive geographical location: Turkey is located in a prime geographical location, making it an ideal destination for patients from around the world, especially from the Middle East, North Africa, and Eastern Europe.

          Facilities provided for patients: The Turkish government provides many facilities for foreign patients, such as easy visas and the possibility of obtaining a free instant translator.

            Affordable prices: The prices of medical services in Turkey are reasonable compared to Western countries, making them an attractive option for patients seeking high-quality treatment at affordable prices.

            These factors contribute to making Turkey a preferred destination for medical tourism, which contributes to the development of the national economy and the creation of new job opportunities.

            The medical tourism sector in Turkey is expected to continue growing in the coming years, making it an ideal destination for patients seeking high-quality treatment at affordable prices.

            Comment (0)

            Leave a Replay

            Please login to leave your comment